[go: up one dir, main page]

WO2013019620A3 - Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody - Google Patents

Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody Download PDF

Info

Publication number
WO2013019620A3
WO2013019620A3 PCT/US2012/048552 US2012048552W WO2013019620A3 WO 2013019620 A3 WO2013019620 A3 WO 2013019620A3 US 2012048552 W US2012048552 W US 2012048552W WO 2013019620 A3 WO2013019620 A3 WO 2013019620A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
inhibitor
ctla
antibody
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/048552
Other languages
French (fr)
Other versions
WO2013019620A2 (en
Inventor
Jeffrey J. Legos
Mark J. CORNFELD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of WO2013019620A2 publication Critical patent/WO2013019620A2/en
Publication of WO2013019620A3 publication Critical patent/WO2013019620A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A combination of anti-neoplastic agents that provides increased activity over monotherapy. In particular, the drug combination that includes an anti-CTLA-4 antibody, in combination with the B-Raf inhibitor N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and MEK inhibitor N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide, or a pharmaceutically acceptable salt or solvate thereof is described.
PCT/US2012/048552 2011-07-29 2012-07-27 Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody Ceased WO2013019620A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512937P 2011-07-29 2011-07-29
US61/512,937 2011-07-29

Publications (2)

Publication Number Publication Date
WO2013019620A2 WO2013019620A2 (en) 2013-02-07
WO2013019620A3 true WO2013019620A3 (en) 2013-04-04

Family

ID=47629856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048552 Ceased WO2013019620A2 (en) 2011-07-29 2012-07-27 Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody

Country Status (1)

Country Link
WO (1) WO2013019620A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150352121A1 (en) * 2013-03-12 2015-12-10 Glaxosmithkline Llc Combination
CN104109159A (en) * 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 New crystal forms of benzene sulfonamide thiazole and preparation method thereof
WO2015085229A1 (en) * 2013-12-08 2015-06-11 Van Andel Research Institute Autophagy inhibitors
WO2016130917A1 (en) * 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
TW201735949A (en) 2016-03-24 2017-10-16 千禧製藥公司 Methods of treating gastrointestinal immune-related adverse events in anti-CTLA4 anti-PD-1 combination treatments
MA44483A (en) 2016-03-24 2019-01-30 Millennium Pharm Inc METHODS FOR TREATING GASTROINTESTINAL ADVERSE EVENTS OF IMMUNE ORIGIN IN ONCOLOGICAL IMMUNE TREATMENTS
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121142A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
US20070020232A1 (en) * 2005-04-26 2007-01-25 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
US20090098135A1 (en) * 2007-09-12 2009-04-16 Marcia Belvin Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US20090298815A1 (en) * 2008-05-06 2009-12-03 Jerry Leroy Adams Benzene Sulfonamide Thiazole and Oxazole Compounds
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121142A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
US20070020232A1 (en) * 2005-04-26 2007-01-25 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
US20090098135A1 (en) * 2007-09-12 2009-04-16 Marcia Belvin Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
US20090298815A1 (en) * 2008-05-06 2009-12-03 Jerry Leroy Adams Benzene Sulfonamide Thiazole and Oxazole Compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EGGERMONT ET AL.: "New drugs in melanoma: It's a whole new world.", EUROPEAN JOURNAL OF CANCER, 2011 *
NATARAJAN ET AL.: "Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma.", DRUGS, vol. 71, no. ISSUE, 9 July 2011 (2011-07-09), pages 1233 - 1250 *

Also Published As

Publication number Publication date
WO2013019620A2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
WO2013019620A3 (en) Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
IL262964B (en) Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
MX2015016592A (en) Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor.
EA201290149A1 (en) COMBINATION
IL266894B (en) Preparation of (s)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl) imidazo [1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide and pharmaceutically acceptable salts thereof
WO2014066606A3 (en) Combination
MX2016007653A (en) Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer.
SG11201808559PA (en) Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
RU2018110770A (en) MDM2 INHIBITORS AND THEIR COMBINATIONS
HUE061448T2 (en) (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidin- Crystalline form of 1-carboxamide hydrogen sulfate
MX2016012365A (en) Combinations.
EP4275752A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
EA201590467A1 (en) MODE OF DOSING OF CEDATIVE MEANS
PH12018502134A1 (en) Methods of treating pediatric cancers
BR112019006228A2 (en) prostate cancer treatment
AR082692A1 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER, PHARMACEUTICAL PRODUCT, EQUIPMENT, KIT
MX2015017629A (en) Pharmaceutical combinations.
WO2012145575A3 (en) Therapy for leukemia
CY1109087T1 (en) IMIDAZO UNION [4,5-C] PYRIDINIS AND ANTI-VICTIVE METHOD
WO2011038380A3 (en) Combination
EA201690762A1 (en) {4- [5- (3-CHLOROPHENOXY) OXAZOLO [5,4-D] PYRIMIDIN-2-IL] -2,6-DIMETHYLPHENOXY} ACETIC ACID FOR USE TO PREVENT OR TREAT ACUTE DAMAGE
RU2015115005A (en) USE OF TETRA-SUBSTITUTED DERIVATIVES [4,3-D] PYRIMIDINE FOR TREATMENT OF DIABETIC NEPHROPATHY
Jiang et al. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines and its molecular mechanisms

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12820682

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12820682

Country of ref document: EP

Kind code of ref document: A2